NCT05851027View on ClinicalTrials.gov

Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 15, 2021

Primary Completion Date

September 10, 2021

Study Completion Date

September 10, 2021

Conditions
Chemotherapy-induced Thrombocytopenia
Interventions
DRUG

QL0911

Qilu investigational product (QL0911 or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.

Trial Locations (1)

200120

Shanghai East Hospital, Shanghai

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT05851027 - Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia | Biotech Hunter | Biotech Hunter